These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16771615)

  • 1. Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection.
    Lalazar G; Ilan Y
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):377-85. PubMed ID: 16771615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
    Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
    Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence.
    Hiroishi K; Ito T; Imawari M
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1473-82. PubMed ID: 18761560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging host cell targets for hepatitis C therapy.
    He Y; Duan W; Tan SL
    Drug Discov Today; 2007 Mar; 12(5-6):209-17. PubMed ID: 17331885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule and novel treatments for chronic hepatitis C virus infection.
    Harrison SA
    Am J Gastroenterol; 2007 Oct; 102(10):2332-8. PubMed ID: 17617208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.
    Veldt BJ; van der Vliet HJ; von Blomberg BM; van Vlierberghe H; Gerken G; Nishi N; Hayashi K; Scheper RJ; de Knegt RJ; van den Eertwegh AJ; Janssen HL; van Nieuwkerk CM
    J Hepatol; 2007 Sep; 47(3):356-65. PubMed ID: 17599630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-virus response and interferon, cytokine systems in patients with chronic hepatitis C].
    Makashova VV; Florianu AI
    Ter Arkh; 2008; 80(11):7-10. PubMed ID: 19143182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future treatment of chronic hepatitis C.
    Keeffe EB
    Antivir Ther; 2007; 12(7):1015-25. PubMed ID: 18018759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C in the advanced adult and elderly subjects.
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Present and future therapy for hepatitis C virus.
    Cornberg M; Deterding K; Manns MP
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):781-93. PubMed ID: 17140355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
    Boo I; Fischer AE; Johnson D; Chin R; Giourouki M; Bharadwaj M; Bowden S; Torresi J; Drummer H
    J Clin Virol; 2007 Aug; 39(4):288-94. PubMed ID: 17569577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for hepatitis C virus infection.
    Soriano V; Peters MG; Zeuzem S
    Clin Infect Dis; 2009 Feb; 48(3):313-20. PubMed ID: 19123867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
    Mihm U; Grigorian N; Welsch C; Herrmann E; Kronenberger B; Teuber G; von Wagner M; Hofmann WP; Albrecht M; Lengauer T; Zeuzem S; Sarrazin C
    Antivir Ther; 2006; 11(4):507-19. PubMed ID: 16856625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maxamine. Histamine dihydrochloride.
    Drugs R D; 1999 Oct; 2(4):274-5. PubMed ID: 10659409
    [No Abstract]   [Full Text] [Related]  

  • 19. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
    Perz JB; Ho AD
    Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic hepatitis C. The Danish Society of Infection Medicine].
    Weis NM; Christensen PB; Laursen AL
    Ugeskr Laeger; 2006 Mar; 168(12):1221. PubMed ID: 16571312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.